Circulating Insulin-like peptide 5 concentrations may reflect colonic exposure to bile acids and help stratify treatment response in patients with chronic diarrhoea, including those with irritable bowel syndrome with diarrhoea and bile acid diarrhoea.
A phase 1 clinical trial found that rizedisben, a fluorescent agent targeting myelin, enabled sustained nerve visualization during robotic prostate surgery at a 3.0 mg/kg dose with minimal side effects.
The Colorectal Cancer Alliance and partners are urging the Department of Health and Human Services to preserve U.S. Preventive Services Task Force’s evidence-based role in safeguarding access to no-cost colorectal cancer screening.
In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.
A new study found colon cancer patients with cannabis use disorder were more than 10 times more likely to die within five years, even after adjusting for age and disease severity.
The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.